Travere Therapeutics, Inc.

TVTX

$624M

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO385 employees

Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 18, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

6 upcoming, 2 past

🎯PDUFANext

FDA PDUFA Date sparsentan (priority)

3/18/2026

For focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date sparsentan (priority)

5/15/2026

For focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. NDA filing. Extracted from SEC filing: 8-K

Source

Phase 2

Pegtibatinase Phase 2 Results Expected

June 2026~Pegtibatinase32

Primary completion for Pegtibatinase trial (NCT03406611) in Homocystinuria

Source

🎯PDUFA

FDA PDUFA Date sparsentan (priority)

7/7/2026

For IgA nephropathy. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date sparsentan (priority)

7/27/2026

For rare kidney disease. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date undisclosed drug candidate (standard)

September 2026~

For undisclosed. NDA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Irbesartan

Phase 3

Focal Segmental Glomerulosclerosis

Dapagliflozin

Phase 3

Immunoglobulin A Nephropathy

Pegtibatinase

Phase 3

Homocystinuria

Sparsentan

Phase 3

Focal Segmental Glomerulosclerosis

RE-021 (Sparsentan)

Phase 2

Focal Segmental Glomerulosclerosis

Drug Name	Phase	Indication	Designations
Irbesartan	Phase 3	Focal Segmental Glomerulosclerosis	-
Dapagliflozin	Phase 3	Immunoglobulin A Nephropathy	-
Pegtibatinase	Phase 3	Homocystinuria	-
Sparsentan	Phase 3	Focal Segmental Glomerulosclerosis	-
RE-021 (Sparsentan)	Phase 2	Focal Segmental Glomerulosclerosis	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

TVTX News